Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vibegron (MK-4618) Efficacy and Safety in Overactive Bladder
NCT01314872Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Mar 2011
- Primary completion
- Oct 2012
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of vibegron in overactive bladder (OAB), sponsored by Merck & Co.. Started Mar 2011; status: completed.
02
Drugs
vibegron
03
Conditions
overactive bladder (OAB)
Beyond the preview
Go deeper on NCT01314872.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01314872.